Purpose: Neurotrophic tyrosine receptor kinase (NTRK) fusions have been described
as oncogenic drivers in a variety of tumors. However, little is known about
the overall frequency of NTRK fusion in unselected pediatric tumors. Here,
we assessed the frequency, fusion partners, and clinical course in
pediatric patients with NTRK fusion-positive tumors.